Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Horses for Courses: Why VCs Stick with Private, Not Public Investing

This article was originally published in Start Up

Executive Summary

With public markets up but private equity markets still in the doldrums, why don't VCs shift their strategies to favor purchasing public biotechs? They have--a bit. But public investing doesn't exploit a VC's competitive advantages or justify the relatively high management fees they charge.

You may also be interested in...

Q&A on Venture Investing During a Public Market Slump

Question: How does the distressed state of the public market for biotech stocks impact venture capital funding of private biotech companies?Answer: Public market conditions should have no material effect on the total amount of venture capital funding available for biotech companies, although it may well have an impact on the investment profile of venture capital fund commitments,

Alternative Financing Mechanisms

With the markets down, it's time to explore alternatives to straight equity deals for public companies: PIPEs, equity lines of credit, convertible debt, and "toxic preferred" securities.

Why Clinical Trials Fail Unexpectedly

Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts